111 related articles for article (PubMed ID: 31026283)
1. Activation of aryl hydrocarbon receptor signaling by a novel agonist ameliorates autoimmune encephalomyelitis.
Abdullah A; Maged M; Hairul-Islam M I; Osama I A; Maha H; Manal A; Hamza H
PLoS One; 2019; 14(4):e0215981. PubMed ID: 31026283
[TBL] [Abstract][Full Text] [Related]
2. Tolerogenic nanoparticles suppress central nervous system inflammation.
Kenison JE; Jhaveri A; Li Z; Khadse N; Tjon E; Tezza S; Nowakowska D; Plasencia A; Stanton VP; Sherr DH; Quintana FJ
Proc Natl Acad Sci U S A; 2020 Dec; 117(50):32017-32028. PubMed ID: 33239445
[TBL] [Abstract][Full Text] [Related]
3. Ambient urban dust particulate matter reduces pathologic T cells in the CNS and severity of EAE.
O'Driscoll CA; Owens LA; Hoffmann EJ; Gallo ME; Afrazi A; Han M; Fechner JH; Schauer JJ; Bradfield CA; Mezrich JD
Environ Res; 2019 Jan; 168():178-192. PubMed ID: 30316103
[TBL] [Abstract][Full Text] [Related]
4. Adenosine A2A receptor agonist ameliorates EAE and correlates with Th1 cytokine-induced blood brain barrier dysfunction via suppression of MLCK signaling pathway.
Liu Y; Alahiri M; Ulloa B; Xie B; Sadiq SA
Immun Inflamm Dis; 2018 Mar; 6(1):72-80. PubMed ID: 29027376
[TBL] [Abstract][Full Text] [Related]
5. A pyrazolopyridine as a novel AhR signaling activator with anti-breast cancer properties in vitro and in vivo.
Abduh MS; Alwassil OI; Aldaqal SM; Alfwuaires MA; Farhan M; Hanieh H
Biochem Pharmacol; 2024 Apr; 222():116079. PubMed ID: 38402910
[TBL] [Abstract][Full Text] [Related]
6. Silencing of aryl hydrocarbon receptor repressor restrains Th17 cell immunity in autoimmune hepatitis.
Gao L; Zhang W; Zhang L; Gromova B; Chen G; Csizmadia E; Cagle C; Nastasio S; Ma Y; Bonder A; Patwardhan V; Robson SC; Jiang S; Longhi MS
J Autoimmun; 2024 Feb; 143():103162. PubMed ID: 38142533
[TBL] [Abstract][Full Text] [Related]
7. Activation of the aryl hydrocarbon receptor inhibits neuropilin-1 upregulation on IL-2-responding CD4
Sandoval S; Malany K; Thongphanh K; Martinez CA; Goodson ML; Souza FDC; Lin LW; Sweeney N; Pennington J; Lein PJ; Kerkvliet NI; Ehrlich AK
Front Immunol; 2023; 14():1193535. PubMed ID: 38035105
[TBL] [Abstract][Full Text] [Related]
8. Prmt5 deficiency inhibits CD4+ T-cell Klf2/S1pr1 expression and ameliorates EAE disease.
Zheng Y; Chen Z; Zhou B; Chen S; Chen N; Shen L
J Neuroinflammation; 2023 Aug; 20(1):183. PubMed ID: 37533053
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of diosgenin in experimental autoimmune encephalomyelitis.
Liu W; Zhu M; Yu Z; Yin D; Lu F; Pu Y; Zhao C; He C; Cao L
J Neuroimmunol; 2017 Dec; 313():152-160. PubMed ID: 29132838
[TBL] [Abstract][Full Text] [Related]
10. Autotaxin in encephalitogenic CD4 T cells as a therapeutic target for multiple sclerosis.
Petersen-Cherubini CL; Murphy SP; Xin M; Liu Y; Deffenbaugh JL; Jahan I; Rau CN; Yang Y; Lovett-Racke AE
Eur J Immunol; 2024 Jan; 54(1):e2350561. PubMed ID: 37850588
[TBL] [Abstract][Full Text] [Related]
11. Induction of indoleamine 2,3-dioxygenase 1 expression in neurons of the central nervous system through inhibition of histone deacetylases blocks the progression of experimental autoimmune encephalomyelitis.
Kim CE; Lee SM; Yoon EH; Won HJ; Jung YJ; Jegal Y; Kim DH; Kwon B; Seo SK
Int Immunopharmacol; 2024 May; 134():112246. PubMed ID: 38759372
[TBL] [Abstract][Full Text] [Related]
12. Smad7 in intestinal CD4
Haupeltshofer S; Leichsenring T; Berg S; Pedreiturria X; Joachim SC; Tischoff I; Otte JM; Bopp T; Fantini MC; Esser C; Willbold D; Gold R; Faissner S; Kleiter I
Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25860-25869. PubMed ID: 31796589
[TBL] [Abstract][Full Text] [Related]
13. Targeting AhR as a Novel Therapeutic Modality against Inflammatory Diseases.
Cannon AS; Nagarkatti PS; Nagarkatti M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008717
[TBL] [Abstract][Full Text] [Related]
14. Thrombin-Induced Microglia Activation Modulated through Aryl Hydrocarbon Receptors.
Sheu ML; Pan LY; Yang CN; Sheehan J; Pan LY; You WC; Wang CC; Pan HC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511175
[TBL] [Abstract][Full Text] [Related]
15. Activation of the aryl hydrocarbon receptor is essential for mediating the anti-inflammatory effects of a novel low-molecular-weight compound.
Lawrence BP; Denison MS; Novak H; Vorderstrasse BA; Harrer N; Neruda W; Reichel C; Woisetschläger M
Blood; 2008 Aug; 112(4):1158-65. PubMed ID: 18270326
[TBL] [Abstract][Full Text] [Related]
16. TCDD Inhibition of IgG1 Production in Experimental Autoimmune Encephalomyelitis (EAE) and In Vitro.
Nicaise AJ; McDonald A; Sears ER; Sturgis T; Kaplan BLF
Antibodies (Basel); 2022 Jan; 11(1):. PubMed ID: 35076460
[TBL] [Abstract][Full Text] [Related]
17. Positive regulation of Vav1 by Themis controls CD4 T cell pathogenicity in a mouse model of central nervous system inflammation.
Marrocco R; Bernard I; Joulia E; Barascud R; Dejean AS; Lesourne R; Saoudi A
Cell Mol Life Sci; 2024 Apr; 81(1):161. PubMed ID: 38565808
[TBL] [Abstract][Full Text] [Related]
18. The activity of the aryl hydrocarbon receptor in T cells tunes the gut microenvironment to sustain autoimmunity and neuroinflammation.
Merchak AR; Cahill HJ; Brown LC; Brown RM; Rivet-Noor C; Beiter RM; Slogar ER; Olgun DG; Gaultier A
PLoS Biol; 2023 Feb; 21(2):e3002000. PubMed ID: 36787309
[TBL] [Abstract][Full Text] [Related]
19. The aryl hydrocarbon receptor and the gut-brain axis.
Barroso A; Mahler JV; Fonseca-Castro PH; Quintana FJ
Cell Mol Immunol; 2021 Feb; 18(2):259-268. PubMed ID: 33408340
[TBL] [Abstract][Full Text] [Related]
20. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27.
Apetoh L; Quintana FJ; Pot C; Joller N; Xiao S; Kumar D; Burns EJ; Sherr DH; Weiner HL; Kuchroo VK
Nat Immunol; 2010 Sep; 11(9):854-61. PubMed ID: 20676095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
